A fork in the path: Developing therapeutic inroads with FoxO proteins.
about
Erythropoietin and diabetes mellitusFoxO Transcription Factors and Regenerative Pathways in Diabetes MellitusShedding new light on neurodegenerative diseases through the mammalian target of rapamycinForkhead box transcription factor 1: role in the pathogenesis of diabetic cardiomyopathyNew Insights for Oxidative Stress and Diabetes MellitusFOXO transcription factors: their clinical significance and regulation.FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis.Oxidative stress: Biomarkers and novel therapeutic pathways.Diabetes mellitus: channeling care through cellular discoveryTranscription Factor Forkhead Regulates Expression of Antimicrobial Peptides in the Tobacco Hornworm, Manduca sextaEarly apoptotic vascular signaling is determined by Sirt1 through nuclear shuttling, forkhead trafficking, bad, and mitochondrial caspase activation.Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways.Novel avenues of drug discovery and biomarkers for diabetes mellitus.EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3β, and β-catenin to foster vascular integrity during experimental diabetes.Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress.Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.Translating cell survival and cell longevity into treatment strategies with SIRT1Back to your heart: ubiquitin proteasome system-regulated signal transductionOxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascadeWISP1 neuroprotection requires FoxO3a post-translational modulation with autoregulatory control of SIRT1Forkhead transcription factors: new considerations for alzheimer's disease and dementia.The vitamin nicotinamide: translating nutrition into clinical care.Silencing of S100A4, a metastasis-associated protein, in endothelial cells inhibits tumor angiogenesis and growth.Modest overexpression of FOXO maintains cardiac proteostasis and ameliorates age-associated functional decline.FoxO1 is crucial for sustaining cardiomyocyte metabolism and cell survival.Programming apoptosis and autophagy with novel approaches for diabetes mellitus.Signaling of reactive oxygen and nitrogen species in Diabetes mellitus.Spontaneous presence of FOXO3-specific T cells in cancer patients.Forkhead Transcription Factors: Formulating a FOXO Target for Cognitive Loss.Characterization of temporal expressions of FOXO and pFOXO proteins in the hippocampus by kainic acid in mice: involvement of NMDA and non-NMDA receptors.Novel Treatment Strategies for the Nervous System: Circadian Clock Genes, Non-coding RNAs, and Forkhead Transcription Factors.FoxO1 is a regulator of MHC-II expression and anti-tumor effect of tumor-associated macrophages.FoxO proteins in the nervous system.
P2860
Q26777878-B2D589ED-8D7C-4863-8E58-F9F4DBB57974Q26800615-56FD82E8-43EE-4452-A54E-B5C0B4C7E5A5Q27015640-EA59E586-BE47-4BA6-861D-88842D802CFDQ28080067-45E69D77-90AE-4BD1-A9DE-DB47BB28D2BDQ28080679-705F6506-83C6-4492-96D2-BDE3261C8308Q33594004-BBB51B11-684C-458B-A47B-A3CB29332674Q33604706-F2017D45-7AA3-485C-B7AC-9EEFE3CFE602Q33682262-623ED760-EE06-426E-A2D2-F6CA3A4A031AQ33749358-D427D1A8-3EC7-4C8C-B4A5-831829089E6BQ33758729-D77EB7AA-713B-4E0A-8FF4-6A210FF3C489Q33877687-463BBFE8-C69B-42B8-8486-7FFC71C8782EQ34185844-DC30A407-7974-4986-8CC6-DEE0F7E8E23DQ34552287-B9AD8FC9-47A0-45C3-842A-F7254D5414D4Q34887803-3316AE1A-D90F-4182-A730-65B5FAB2384AQ35146283-1FB13A9C-81C3-4574-96FB-1F75BCE935C4Q35157985-0DE430BA-6D5F-4018-A95E-12002D37C16FQ35660308-2DC4E60F-2207-49EB-BFBF-0C78B273B88EQ35803035-1BBB944B-D094-4DEB-9E39-CFB5DC6F6029Q36432388-4B08AF29-7666-448C-932D-40E3A4EBE629Q36597808-F379844E-993D-42DC-AEAB-98C30243C9B4Q37064987-5E2A850B-B9D9-45DE-B3BA-F56BC2F22197Q37374047-58DC07A8-4F11-4394-B2F5-65E30204CB53Q37502777-89614DEE-B228-47FF-9601-C7CD2618B522Q37592017-6DC8D7C3-ED69-42B2-B19C-F79C34F501AFQ38069459-96B521FE-D189-4030-B219-0319DB15246DQ38367977-AA7A14C1-15F1-4DD1-9F58-A1218782E09DQ41870434-FB948461-1D54-490E-BECB-4B13AEF23FE3Q43196241-E74B2215-8269-455F-ABD8-7A1AC8626FFAQ45305554-2C24EF09-621E-4133-AE35-FA75D89E2B0FQ48827215-2787B0C9-3035-4608-AF72-490E1A4B1F5AQ51761339-931F9613-89E6-4022-BC8B-C8D9428EB52FQ52751628-96FDC2B0-D4FA-4E3E-9F47-041861D24E78Q53622309-6B833426-EC94-4D1D-B71E-6987DD790F9F
P2860
A fork in the path: Developing therapeutic inroads with FoxO proteins.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A fork in the path: Developing therapeutic inroads with FoxO proteins.
@en
A fork in the path: Developing therapeutic inroads with FoxO proteins.
@nl
type
label
A fork in the path: Developing therapeutic inroads with FoxO proteins.
@en
A fork in the path: Developing therapeutic inroads with FoxO proteins.
@nl
prefLabel
A fork in the path: Developing therapeutic inroads with FoxO proteins.
@en
A fork in the path: Developing therapeutic inroads with FoxO proteins.
@nl
P2093
P2860
P356
P1476
A fork in the path: Developing therapeutic inroads with FoxO proteins.
@en
P2093
Jinling Hou
Kenneth Maiese
Yan Chen Shang
Zhao Zhong Chong
P2860
P304
P356
10.4161/OXIM.2.3.8916
P577
2009-07-01T00:00:00Z